Literature DB >> 27650951

Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation.

Semih Can Akıncılar1,2, Ekta Khattar1, Priscilla Li Shan Boon3, Bilal Unal1,2, Melissa Jane Fullwood3, Vinay Tergaonkar4,2,5.   

Abstract

Cancer-specific TERT promoter mutations (-146C>T and -124C>T) have been linked to reactivation of the epigenetically silenced telomerase reverse transcriptase gene (TERT). Understanding how these single-nucleotide alterations drive TERT reactivation is a fundamental unanswered question and is key for making successful therapeutics. We show that unlike wild-type promoters, recruitment of the transcription factor GABPA specifically to mutant TERT promoters mediates long-range chromatin interaction and enrichment of active histone marks, and hence drives TERT transcription. CRISPR-mediated reversal of mutant TERT promoters, or deletion of its long-range interacting chromatin, abrogates GABPA binding and long-range interactions, leading to depletion of active histone marks, loss of POL2 recruitment, and suppression of TERT transcription. In contrast, de novo introduction of a TERT promoter mutation enables GABPA binding and upregulation of TERT via long-range interactions, acquisition of active histone marks, and subsequent POL2 recruitment. This study provides a unifying mechanistic insight into activation of mutant TERT promoters across various human cancers. SIGNIFICANCE: This study identifies a key mechanism by which cancer-specific mutant TERT promoters cause reactivation of TERT Because the mechanism uncovered here is not utilized by promoters that drive TERT in normal cells, this mechanism could be exploited to make inhibitors which have the potential to block telomerase function and hence the progression of up to 90% of human cancers. Cancer Discov; 6(11); 1276-91. ©2016 AACR.See related commentary by Min and Shay, p. 1212This article is highlighted in the In This Issue feature, p. 1197. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27650951     DOI: 10.1158/2159-8290.CD-16-0177

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  70 in total

Review 1.  Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends.

Authors:  Song My Hoang; Roderick J O'Sullivan
Journal:  Trends Cancer       Date:  2020-01-23

Review 2.  When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.

Authors:  Saumya R Bollam; Michael E Berens; Harshil D Dhruv
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-10       Impact factor: 5.081

3.  TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.

Authors:  Jaewon Min; Jerry W Shay
Journal:  Cancer Discov       Date:  2016-11       Impact factor: 39.397

4.  Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.

Authors:  Yinghui Li; Hui Shan Cheng; Wee Joo Chng; Vinay Tergaonkar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-23       Impact factor: 11.205

5.  TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.

Authors:  Neeraj Agarwal; Sebastien Rinaldetti; Bassem B Cheikh; Qiong Zhou; Evan P Hass; Robert T Jones; Molishree Joshi; Daniel V LaBarbera; Simon R V Knott; Thomas R Cech; Dan Theodorescu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-21       Impact factor: 11.205

Review 6.  Dysfunctional telomeres and hematological disorders.

Authors:  Elena Fiorini; Andrea Santoni; Simona Colla
Journal:  Differentiation       Date:  2018-01-04       Impact factor: 3.880

7.  Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Authors:  Valentina Maggisano; Marilena Celano; Saverio Massimo Lepore; Marialuisa Sponziello; Francesca Rosignolo; Valeria Pecce; Antonella Verrienti; Federica Baldan; Catia Mio; Lorenzo Allegri; Marianna Maranghi; Rosa Falcone; Giuseppe Damante; Diego Russo; Stefania Bulotta
Journal:  Endocrine       Date:  2019-01-19       Impact factor: 3.633

8.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.

Authors:  Andrew Mancini; Ana Xavier-Magalhães; Wendy S Woods; Kien-Thiet Nguyen; Alexandra M Amen; Josie L Hayes; Christof Fellmann; Michael Gapinske; Andrew M McKinney; Chibo Hong; Lindsey E Jones; Kyle M Walsh; Robert J A Bell; Jennifer A Doudna; Bruno M Costa; Jun S Song; Pablo Perez-Pinera; Joseph F Costello
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

Review 9.  Non-duplex G-Quadruplex Structures Emerge as Mediators of Epigenetic Modifications.

Authors:  Ananda Kishore Mukherjee; Shalu Sharma; Shantanu Chowdhury
Journal:  Trends Genet       Date:  2018-12-04       Impact factor: 11.639

Review 10.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.